Epoprostenol Sodium Patent Expiration
Epoprostenol Sodium was first introduced by Glaxosmithkline Llc
Epoprostenol Sodium Patents
Given below is the list of patents protecting Epoprostenol Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Veletri | US8318802 | Epoprostenol formulation and method of making thereof | Mar 15, 2027 | Actelion |
| Veletri | US8598227 | Epoprostenol formulation and method of making thereof | Feb 02, 2027 | Actelion |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Epoprostenol Sodium's patents.
Latest Legal Activities on Epoprostenol Sodium's Patents
Given below is the list recent legal activities going on the following patents of Epoprostenol Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 May, 2024 | US8318802 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 May, 2021 | US8598227 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 May, 2020 | US8318802 |
| Email Notification Critical | 05 Sep, 2014 | US8598227 |
| Change in Power of Attorney (May Include Associate POA) Critical | 05 Sep, 2014 | US8598227 |
| Filing Receipt - Replacement | 05 Sep, 2014 | US8598227 |
| Electronic Review Critical | 23 Jul, 2014 | US8598227 |
| Email Notification Critical | 23 Jul, 2014 | US8598227 |
| Mail Pre-Exam Notice | 23 Jul, 2014 | US8598227 |
| Change in Power of Attorney (May Include Associate POA) Critical | 22 Jul, 2014 | US8318802 |
Epoprostenol Sodium's Family Patents
Explore Our Curated Drug Screens
Epoprostenol Sodium Generic API Manufacturers
Several generic applications have been filed for Epoprostenol Sodium. The first generic version for Epoprostenol Sodium was by Meitheal Pharmaceuticals Inc and was approved on Apr 23, 2008. And the latest generic version is by Mylan Pharmaceuticals Inc and was approved on Jun 12, 2024.
Given below is the list of companies who have filed for Epoprostenol Sodium generic, along with the locations of their manufacturing plants worldwide.
1. MEITHEAL
Meitheal Pharmaceuticals Inc has filed for 2 different strengths of generic version for Epoprostenol Sodium. Given below are the details of the strengths of this generic introduced by Meitheal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 1.5MG BASE/VIAL | injectable | Prescription | INJECTION | AP1 | Apr 23, 2008 |
| EQ 0.5MG BASE/VIAL | injectable | Prescription | INJECTION | AP1 | Apr 23, 2008 |
2. MYLAN
Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Epoprostenol Sodium. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 1.5MG BASE/VIAL | injectable | Prescription | INJECTION | AP2 | Jun 12, 2024 |
| EQ 0.5MG BASE/VIAL | injectable | Prescription | INJECTION | AP2 | Jun 12, 2024 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
| Canada |
| |||||||||||||||||
| Ireland |
| |||||||||||||||||
3. SUN PHARM
Sun Pharmaceutical Industries Ltd has filed for 2 different strengths of generic version for Epoprostenol Sodium. Given below are the details of the strengths of this generic introduced by Sun Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.5MG BASE/VIAL
(reference standard) | injectable | Prescription | INJECTION | AP2 | Jan 15, 2021 |
| EQ 1.5MG BASE/VIAL | injectable | Prescription | INJECTION | AP2 | Jan 15, 2021 |
Manufacturing Plant Locations New
Sun Pharm's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Sun Pharm as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||||||||||||
| India |
| |||||||||||||||||||||||||||||